Lyra Therapeutics, Inc. (LYRA)
LYRA Stock Price Chart
Explore Lyra Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze LYRA price movements and trends.
LYRA Company Profile
Discover essential business fundamentals and corporate details for Lyra Therapeutics, Inc. (LYRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
1 May 2020
Employees
30.00
Website
https://lyratherapeutics.comCEO
Maria Palasis
Description
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
LYRA Financial Timeline
Browse a chronological timeline of Lyra Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Mar 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$5.98.
Earnings released on 12 Aug 2025
EPS came in at -$5.51 surpassing the estimated -$5.79 by +4.84%, while revenue for the quarter reached $183.00K , beating expectations by +18.64%.
Stock split effective on 28 May 2025
Shares were split 1 : 50 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 6 May 2025
EPS came in at -$6.00 surpassing the estimated -$7.50 by +20.00%, while revenue for the quarter reached $183.00K , beating expectations by +13.43%.
Earnings released on 13 Mar 2025
EPS came in at -$0.16 falling short of the estimated -$0.13 by -23.08%, while revenue for the quarter reached $209.00K , beating expectations by +1.46%.
Earnings released on 12 Nov 2024
EPS came in at -$0.18 surpassing the estimated -$0.23 by +21.74%, while revenue for the quarter reached $195.00K , missing expectations by -4.79%.
Earnings released on 14 Aug 2024
EPS came in at -$0.29 surpassing the estimated -$0.34 by +14.71%, while revenue for the quarter reached $598.00K , beating expectations by +70.86%.
Earnings released on 30 Apr 2024
EPS came in at -$0.35 falling short of the estimated -$0.26 by -34.62%, while revenue for the quarter reached $532.00K , beating expectations by +54.24%.
Earnings released on 21 Mar 2024
EPS came in at -$0.22 surpassing the estimated -$0.33 by +33.33%, while revenue for the quarter reached $146.00K , missing expectations by -62.45%.
Earnings released on 7 Nov 2023
EPS came in at -$0.27 surpassing the estimated -$0.33 by +18.18%, while revenue for the quarter reached $544.00K , beating expectations by +39.49%.
Earnings released on 8 Aug 2023
EPS came in at -$0.33 surpassing the estimated -$0.44 by +25.00%, while revenue for the quarter reached $458.00K , beating expectations by +227.14%.
Earnings released on 12 May 2023
EPS came in at -$0.44 falling short of the estimated -$0.36 by -22.22%, while revenue for the quarter reached $410.00K , beating expectations by +156.25%.
Earnings released on 29 Mar 2023
EPS came in at -$0.36 surpassing the estimated -$0.42 by +14.29%, while revenue for the quarter reached $11.00K , missing expectations by -92.67%.
Earnings released on 8 Nov 2022
EPS came in at -$0.40 surpassing the estimated -$0.42 by +4.76%, while revenue for the quarter reached $359.00K , beating expectations by +252.83%.
Earnings released on 9 Aug 2022
EPS came in at -$0.43 falling short of the estimated -$0.34 by -26.47%, while revenue for the quarter reached $407.00K , missing expectations by -71.63%.
Earnings released on 10 May 2022
EPS came in at -$0.54 surpassing the estimated -$0.92 by +41.30%, while revenue for the quarter reached $5.37M , beating expectations by +100.00%.
Earnings released on 9 Mar 2022
EPS came in at -$1.05 falling short of the estimated -$0.82 by -28.05%, while revenue for the quarter reached $271.00K , missing expectations by -75.91%.
Earnings released on 9 Nov 2021
EPS came in at -$0.85 falling short of the estimated -$0.78 by -8.97%, while revenue for the quarter reached $14.00K , missing expectations by -96.50%.
Earnings released on 9 Aug 2021
EPS came in at -$0.85 falling short of the estimated -$0.61 by -39.34%.
Earnings released on 11 May 2021
EPS came in at -$0.60 falling short of the estimated -$0.48 by -25.00%.
Earnings released on 9 Mar 2021
EPS came in at -$0.46 surpassing the estimated -$0.61 by +24.59%.
Earnings released on 10 Nov 2020
EPS came in at -$0.49 falling short of the estimated -$0.48 by -2.08%.
LYRA Stock Performance
Access detailed LYRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.